Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRR | Q9GZT4 | 4/20 | 0.71 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.68 |
| ▸ | PPARG | P37231 | 11/20 | 0.59 |
| ▸ | PPARA | Q07869 | 10/20 | 0.59 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11298237 | 0.84 | SRR (0.73) | SRRPSAT1PPARGPPARA | |
| Aminooxyphenylpropionate SCHEMBL1401589 | 0.83 | SRR (1.00) | SRRPSAT1PPARGPPARA | |
| Aminooxyphenylpropionate SCHEMBL1520985 | 0.83 | SRR (1.00) | SRRPSAT1PPARGPPARA | |
| Aminooxyphenylpropionate SCHEMBL6513696 | 0.83 | SRR (1.00) | SRRPSAT1PPARGPPARA | |
| SCHEMBL15446243 | 0.82 | SRR (0.71) | SRRPSAT1PPARGPPARA | |
| Bromide SCHEMBL11297122 | 0.82 | SRR (0.71) | SRRPSAT1PPARGPPARA | |
| Aminooxyphenylpropionate SCHEMBL1357763 | 0.81 | SRR (0.96) | SRRPSAT1PPARGPPARA | |
| SCHEMBL15446290 | 0.81 | HDAC1 (0.49) | SRRPSAT1PPARGPPARAMMP1 | |
| SCHEMBL15446238 | 0.81 | SRR (1.00) | SRRPSAT1PPARGPPARAPPARD | |
| SCHEMBL15446229 | 0.78 | SRR (0.75) | SRRPSAT1PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9259000-B2 | Auxin biosynthesis inhibitor | RIKEN (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9259000-B2 | Auxin biosynthesis inhibitor | RIKEN (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20140031230-A1 | AUXIN BIOSYNTHESIS INHIBITOR | Riken Public University Corporation Yokohama City University | 2014-01-30 | — | — | US | disclosed |
| US-20140031230-A1 | AUXIN BIOSYNTHESIS INHIBITOR | Riken Public University Corporation Yokohama City University | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031230-A1 | AUXIN BIOSYNTHESIS INHIBITOR | AGXT, AOX1, FDPS | SRR 169/4885PSAT1 186/4885PPARG 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.